Pharmaceutical governance system for costly drugs through human rights due diligence
27 November 2025
Katrina Perehudoff co-authored a new publication in The BMJ examining how a human rights due diligence framework could strengthen pharmaceutical governance and improve access to costly new drugs.
Key messages
-
A pharmaceutical governance system grounded in international human rights, particularly the right to health and access to drugs, could help achieve equitable access to costly drugs
-
A human rights due diligence approach could be used to promote government compliance with human rights while working towards national and international legislation
-
This approach could also be used to ensure corporate action to promote availability, accessibility, acceptability, and quality of drugs for rare diseases